• Explore /
  • Poster
  • / Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).

Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Howard I. Scher

Memorial Sloan Kettering Cancer Center, New York, NY

Howard I. Scher , Ryon P Graf , Nicole A. Schreiber , Eric Winquist , Brigit McLaughlin , David Lu , Sarah Orr , Martin Fleisher , Lori Lowes , Amanda K. L. Anderson , Yipeng Wang , Ryan Vance Dittamore , Alison L Allan , Gerhardt Attard , Glenn Heller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 273)

DOI

10.1200/JCO.2018.36.6_suppl.273

Abstract #

273

Poster Bd #

N5

Abstract Disclosures

Similar Posters

First Author: Howard I. Scher

First Author: Valeria Maldonado Grijalva

Poster

2019 Genitourinary Cancers Symposium

Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).

Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Edmond Michael Kwan

First Author: Emmanuel S. Antonarakis